How SARS-CoV-2 uses a host protein to replicate itself
Molecular Mechanism of Folding of Nsp12 and Assembly of the SARS-CoV-2 RNA Polymerase Complex by the Cytosolic Chaperonin CCT
['FUNDING_R15'] · BRIGHAM YOUNG UNIVERSITY · NIH-11042487
This study is looking at how the SARS-CoV-2 virus uses a specific protein in our cells to help itself make copies, and by figuring this out, researchers hope to find new ways to stop the virus from spreading.
Quick facts
| Phase | ['FUNDING_R15'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BRIGHAM YOUNG UNIVERSITY (nih funded) |
| Locations | 1 site (PROVO, UNITED STATES) |
| Trial ID | NIH-11042487 on ClinicalTrials.gov |
What this research studies
This research investigates how the SARS-CoV-2 virus hijacks a host cell protein called CCT to replicate. By understanding the molecular mechanisms involved, the study aims to uncover how the virus assembles its RNA polymerase complex, which is crucial for its replication. The approach involves examining the interactions between the viral proteins and the host chaperone system, utilizing biochemical techniques to analyze these processes. This knowledge could lead to the development of new antiviral strategies targeting these interactions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals affected by COVID-19 or those at high risk of severe illness from the virus.
Not a fit: Patients who are not infected with SARS-CoV-2 or those who have already recovered from COVID-19 may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that inhibit the replication of SARS-CoV-2, potentially improving outcomes for patients with COVID-19.
How similar studies have performed: Other research has successfully demonstrated the role of host chaperones in viral replication, indicating that this approach has potential for meaningful advancements in antiviral therapies.
Where this research is happening
PROVO, UNITED STATES
- BRIGHAM YOUNG UNIVERSITY — PROVO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WILLARDSON, BARRY M — BRIGHAM YOUNG UNIVERSITY
- Study coordinator: WILLARDSON, BARRY M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus